The Need to Examine Metastatic Tissue at the Time of Progression of Breast Cancer: Is Re-biopsy a Necessity or a Luxury?

被引：31

作者：

Khasraw, Mustafa ^{[1
]}

Brogi, Edi ^{[1
]}

Seidman, Andrew D. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Evelyn H Lauder Breast & Imaging Ctr, New York, NY 10065 USA

来源：

CURRENT ONCOLOGY REPORTS | 2011年 / 13卷 / 01期

关键词：

Tissue biopsy; Metastases; Breast cancer; Estrogen receptor; ER; Progesterone receptor; PgR; Human epidermal growth factor receptor-2; HER2; PATHOLOGISTS GUIDELINE RECOMMENDATIONS; ESTROGEN-RECEPTOR; PROGESTERONE-RECEPTOR; AMERICAN-SOCIETY; HER-2/NEU STATUS; FIXATION TIME; HER2; STATUS; THERAPY; DISCORDANCE; TUMOR;

D O I：

10.1007/s11912-010-0137-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Knowledge of estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor-2 (HER2) status is necessary for determining the optimal treatment of breast cancer patients. At the same time, the discordance between marker profiles (ER/PR and HER2) of primary and metastatic breast cancer is well documented. Whether discordant cases are secondary to "clonal selection" in the face of targeted anti-estrogen or anti-HER2 therapy or whether they are a laboratory artifact is still debated; both scenarios are likely. This article outlines current modalities for ER, PR, and HER2 testing in primary breast carcinoma and its metastases and reviews prospective and retrospective studies that have addressed these issues, as well as recent advances in the field.

引用

页码：17 / 25

页数：9

共 50 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2] Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? [J].

Amir, Eitan ;

Clemons, Mark .

LANCET ONCOLOGY, 2009, 10 (10) :933-935

[3]

[Anonymous], 2010, J CLIN ONCOL, DOI DOI 10.1200/JCO.2010.28.15_SUPPL.1007

[4] Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC) [J].

Arnedos, M. ;

Nerurkar, A. ;

Osin, P. ;

A'Hern, R. ;

Smith, I. E. ;

Dowsett, M. .

ANNALS OF ONCOLOGY, 2009, 20 (12) :1948-1952

[5] Intratumor Heterogeneity and Precision of Microarray-Based Predictors of Breast Cancer Biology and Clinical Outcome [J].

Barry, William T. ;

Kernagis, Dawn N. ;

Dressman, Holly K. ;

Griffis, Ryan J. ;

Hunter, J'Vonne D. ;

Olson, John A. ;

Marks, Jeff R. ;

Ginsburg, Geoffrey S. ;

Marcom, Paul K. ;

Nevins, Joseph R. ;

Geradts, Joseph ;

Datto, Michael B. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2198-2206

[6] Third consensus on medical treatment of metastatic breast cancer [J].

Beslija, S. ;

Bonneterre, J. ;

Burstein, H. J. ;

Cocquyt, V. ;

Gnant, M. ;

Heinemann, V. ;

Jassem, J. ;

Koestler, W. J. ;

Krainer, M. ;

Menard, S. ;

Petit, T. ;

Petruzelka, L. ;

Possinger, K. ;

Schmid, P. ;

Stadtmauer, E. ;

Stockler, M. ;

Van Belle, S. ;

Vogel, C. ;

Wilcken, N. ;

Wiltschke, C. ;

Zielinski, C. C. ;

Zwierzina, H. .

ANNALS OF ONCOLOGY, 2009, 20 (11) :1771-1785

[7]

Broom RJ, 2009, ANTICANCER RES, V29, P1557

[8] Accurately Assessing HER-2/neu Status in Needle Core Biopsies of Breast Cancer Patients in the Era of Neoadjuvant Therapy: Emerging Questions and Considerations Addressed [J].

D'Alfonso, Timothy ;

Liu, Yi-Fang ;

Monni, Stefano ;

Rosen, Paul Peter ;

Shin, Sandra J. .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2010, 34 (04) :575-581

[9] Management of breast cancer with targeted agents: importance of heterogenicity [J].

Di Cosimo, Serena ;

Baselga, Jose .

NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (03) :139-147

[10] Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites [J].

Gancberg, D ;

Di Leo, A ;

Cardoso, F ;

Rouas, G ;

Pedrocchi, M ;

Paesmans, M ;

Verhest, A ;

Bernard-Marty, C ;

Piccart, MJ ;

Larsimont, D .

ANNALS OF ONCOLOGY, 2002, 13 (07) :1036-1043

← 1 2 3 4 5 →